62168 Federal Register / Vol. 79, No. 200 / Thursday, October 16, 2014 / Notices 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: October 9, 2014. 

Carolyn Baum, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2014–24601 Filed 10–15–14; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Human Genome Research 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Inherited 

Disease Research Access Committee. 

Date: October 29, 2014. 

Time: 10:00 a.m. to 11:00 a.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 5635 

Fishers Lane, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Ken Nakamura, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, National Human Genome Research 

Institute, National Institutes of Health, 5635 

Fishers Lane, Suite 4076, MSC 9306, 

Rockville, MD 20852, 301–402–0838. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.172, Human Genome 

Research, National Institutes of Health, HHS) 

Dated: October 10, 2014. 

David Clary, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2014–24605 Filed 10–15–14; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Exclusive Option 

License: The Development of a Single 

Domain Human Anti-Mesothelin 

Monoclonal Antibody for the Treatment 

of Human Cancers 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: This is notice, in accordance 

with 35 U.S.C. 209 and 37 CFR part 404, 

that the National Institutes of Health, 

Department of Health and Human 

Services, is contemplating the grant of 

an exclusive start-up option license to 

practice the inventions embodied in 

U.S. Patent Application 61/706,396 

entitled ‘‘Mesothelin Antibodies And 

Methods For Eliciting Potent Antitumor 

Activity’’ [HHS Ref. E–236–2012/0–US– 

01], PCT Application PCT/US2013/

059883 entitled ‘‘Mesothelin Antibodies 

And Methods For Eliciting Potent 

Antitumor Activity’’ [HHS Ref. E–236– 

2012/0–PCT–02], and all related 

continuing and foreign patents/patent 

applications for the technology family, 

to H2Bio, Inc. The patent rights in these 

inventions have been assigned to and/or 

exclusively licensed to the Government 

of the United States of America. 

The prospective exclusive start-up 

option licensed territory may be 

worldwide, and the field of use may be 

limited to: 

The use of SD1-serine protease 

immunoconjugates for the treatment of 

mesothelioma, pancreatic cancer, ovarian 

cancer and lung adenocarcinoma, including 

combination therapies using the SD1-serine 

protease immunoconjugate, wherein the 

serine protease is Granzyme B (GrB) or a 

Derivative thereof. 

Upon the expiration or termination of 

the exclusive start-up option license, 

H2Bio, Inc. will have the exclusive right 

to execute an exclusive 

commercialization license which will 

supersede and replace the exclusive 

start-up option license with no greater 

field of use and territory than granted in 

the exclusive start-up option license. 

DATES: Only written comments and/or 

applications for a license which are 

received by the NIH Office of 

Technology Transfer on or before 

October 31, 2014 will be considered. 

ADDRESSES: Requests for copies of the 

patent application, inquiries, comments, 

and other materials relating to the 

contemplated exclusive license should 

be directed to: David A. Lambertson, 

Ph.D., Senior Licensing and Patenting 

Manager, Office of Technology Transfer, 

National Institutes of Health, 6011 

Executive Boulevard, Suite 325, 

Rockville, MD 20852–3804; Telephone: 

(301) 435–4632; Facsimile: (301) 402– 

0220; Email: lambertsond@mail.nih.gov. 

SUPPLEMENTARY INFORMATION: This 

invention concerns a monoclonal 

antibody and methods of using the 

antibody for the treatment of 

mesothelin-expressing cancers, 

including mesothelioma, lung cancer, 

ovarian cancer and pancreatic cancer. 

The specific antibody covered by this 

technology is designated SD1, which is 

a single domain, fully human 

monoclonal antibody against 

mesothelin. 

Mesothelin is a cell surface antigen 

that is preferentially expressed on 

certain types of cancer cells. The SD1 

antibody can selectively bind to these 

cancer cells and induce cell death while 

leaving healthy, essential cells 

unharmed. This can result in an 

effective therapeutic strategy with fewer 

side effects due to less non-specific 

killing of cells. 

The prospective exclusive start-up 

option license will be royalty bearing 

and will comply with the terms and 

conditions of 35 U.S.C. 209 and 37 CFR 

Part 404. The prospective exclusive 

start-up option license may be granted 

unless the NIH receives written 

evidence and argument that establishes 

that the grant of the license would not 

be consistent with the requirements of 

35 U.S.C. 209 and 37 CFR Part 404 

within fifteen (15) days from the date of 

this published notice. 

Complete applications for a license in 

the field of use filed in response to this 

notice will be treated as objections to 

the grant of the contemplated exclusive 

start-up option license. Comments and 

objections submitted to this notice will 

not be made available for public 

inspection and, to the extent permitted 

by law, will not be released under the 

Freedom of Information Act, 5 U.S.C. 

552. 

Dated: October 8, 2014. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 2014–24501 Filed 10–15–14; 8:45 am] 

BILLING CODE 4140–01–P 


asabaliauskas on DSK5VPTVN1PROD with NOTICES